Overview

Progression can be deadly. Think beyond surveillance.

Barrx™ radiofrequency ablation system is designed to precisely eradicate the Barrett’s epithelium.1 Barrett's esophagus patients with low-grade dyplasia treated with RFA have a substantial reduction in progression compared to patients who undergo surveillance alone.2

The Barrx™ radiofrequency ablation system includes the Barrx™ flex RFA energy generator and a family of ablation catheters.

Barrx™ risk stratification brochure

View Brochure

The power to make a difference​

Eradicate Barrett’s esophagus for patients with low-grade dysplasia and reduce the relative risk of disease progression to high-grade dysplasia and esophageal adenocarcinoma by up to 94% with the Barrx™ radiofrequency ablation system.2,3,7,†

Major GI societies endorse radiofrequency ablation in the treatment guidelines ​for Barrett’s esophagus. With demonstrated efficacy, safety,1 and support from leading institutions8,9 this technology allows you to act with confidence.

When risk of progression is high, proactively treat with the Barrx™ radiofrequency ablation system.

Think beyond surveillance​

Progression of Barrett’s esophagus to esophageal adenocarcinoma (EAC) can ​be deadly.10 Surveillance may not be enough for some patients.​

Clinical data has identified several risk factors that contribute to disease progression, including:​

  • Dysplasia2,3
  • Family history of Barrett’s esophagus or EAC​4
  • Long-segment disease​5
  • Smoking tobacco6

One generator. Multiple solutions.

The Barrx™ flex RFA energy generator is a bipolar radiofrequency generator that provides the flexibility to chose either the Barrx™ 360 express RFA balloon catheter for larger treatment areas or Barrx™ RFA focal catheters for smaller focal areas.

Our product portfolio 

Barrx™ flex RFA energy generator

The Barrx™ radiofrequency ablation system includes the Barrx™ flex RFA energy generator and a family of ablation catheters which are designed to control depth and uniformity of gastrointestinal (GI) tissue ablation.

Barrx™ 360 express RFA balloon catheter

The Barrx™ 360 express RFA balloon catheter features a self-adjusting ablation balloon that eliminates the sizing process.

Barrx™ RFA focal catheters

The Barrx™ RFA focal catheter enables physicians to provide primary treatment for short and intermediate length segments of non-circumferential Barrett's esophagus or provide secondary treatment after ablation with the Barrx™ 360 RFA balloon catheter (or other therapeutic devices).

Barrx™ channel RFA endoscopic catheter

The Barrx™ channel RFA endoscopic catheter delivers radiofrequency ablation, after being placed through the working channel of a flexible endoscope.

Barrx™ RFA accessories

Barrx™ accessories include endoscopic guidewires, cleaning caps, and a cart to hold ablation equipment.

Order Information
ORDER CODE DESCRIPTION UNIT OF MEASURE QUANTITY
1190A-115A Barrx™ flex RFA energy generator, 115V. Contains 1 Barrx™ flex RFA footswitch and 1 Barrx™ flex RFA output cable included with each generator. Each 1
1190A-230A Barrx™ flex RFA energy generator, 230V. Contains 1 Barrx™ flex RFA footswitch and 1 Barrx™ flex RFA output cable included with each generator.
Each 1
FLEXFS-010A Barrx™ flex RFA footswitch, 10' (3 m) Each 1
FLEXCC-020A Barrx™ flex RFA output cable, 9' (2.7 m) Each 1
64082 Barrx™ RFA self-sizing balloon catheter Box 1
90-9300 Barrx™ 60 RFA focal catheter Each 1
90-9100 Barrx™ 90 RFA focal catheter Each 1
90-9200 Barrx™ ultra-long RFA focal catheter Each 1
TTS-1100 Channel RFA endoscopic catheter Each 1
GW-002B 0.038" (0.097 cm) x 260 cm Each 1
GW-005M 0.038” (0.097 cm) x 230 cm with depth markings 230 cm Each 1
CP-001A Small: 8.8 mm to 9.7 mm
Compatible olympus endoscope models: GIF-160, GIF-Q180, GIF-Q160
Box 10
CP-002A Medium: 9.8 mm to 11.1 mm
Compatible olympus endoscope models: GIF-H180
Box 10
CART-100 Barrx™ RFA cart Each 1
Specifications: Barrx™ 360 express RFA balloon catheter
General Characteristics and Compatibility
Part number 64082
Electrode length 4 cm
Balloon length 8 cm
Device diameter range 18-31 mm
Balloon max pressure 4 psi
Generator compatibility Barrx™ flex RFA energy generator only
Number of ablations 16
Generator energy setting 10J/cm2
Guidewire compatibility Stiff wire, .035”-.039” in diameter
Expiration 6 hours after first inflation, 3-year shelf life
Specifications: Barrx™ 60 RFA focal catheter
Physical Characteristics
Recommended scope sizes 8.6 mm to 9.8 mm
Electrode dimensions 15 mm length x 10 mm width
Catheter shaft length 160 cm
Catheter shaft diameter 4 mm
Specifications: Barrx™ 90 RFA focal catheter
Phsyical characteristics
Recommended scope sizes 8.6 mm to 12.8 mm
Electrode dimensions 20 mm length x 13 mm width
Catheter shaft length 160 cm
Catheter shaft diameter 4 mm
General Characteristics
Single-patient use
Up to 80 ablation treatments per session
Fits on distal end of a flexible endoscope
Specifications: Barrx™ ultra long RFA focal catheter
Physical Characteristics
Recommended scope sizes 8.6 mm to 9.8 mm
Electrode dimensions 40 mm length x 13 mm width
Catheter shaft length 160 cm
Catheter shaft diameter 4 mm
Specifications: Barrx™ channel RFA endoscopic catheter
Physical Characteristics and Compatibility
Catheter usable length 135 cm
Electrode dimensions 7.5 mm x 15.7 mm
Endoscope working channel diameter 2.8 mm or larger
Maximum endoscope working channel length 126 cm
Endoscope compatibility Olympus®, Pentax® and Fujinon®
Generator compatibility Barrx™ Flex RFA energy generator
General Characteristics
Single-patient use
Up to 120 ablation treatments per session
Specifications: Barrx™ RFA endoscopic guidewires
General Characteristics
Packaged individually
Supplied sterile for single use
Coated stainless steel core
Straight, flexible, distal tip
Specifications: Barrx™ RFA cart
Physical CHARACTERISTICS
Height 42.5"
Width 22.5" (34" with trays)
Depth 23"
Net weight 100 lbs.
Product Storage Capacity
Quantity 18-Barrx™ 360 RFA balloon catheter/360 express RFA balloon catheter
Quantity 12-Barrx™ RFA focal catheters or Barrx™ RFA endoscopic guidewire

Order Information

TRANSFORM ESOPHAGEAL CARE

Our comprehensive solutions can assist you in the assessment and treatment of esophageal patients.

Patient resources

Find patient information about Barrett's esophagus, GERD, acid reflux, and related treatments and therapies.

  • †94% is the calculated relative risk reduction [(26-1.5)/26] = 25/26 *100. From [25.0% (1.5% for ablation vs 26.5% for control; 95%CI, 14.1%-35.9%; P < .001].

  • 1. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy. 2010;42:781-9.

  • 2. Phoa KN, van Vilsteren FG, Pouw RE, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;26;311(12):1209-17.

  • 3. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009; 28;360(22):2277-88.

  • 4. Tofani C, Gandhi K, Spataro J, et al. Esophageal adenocarcinoma in a first-degree relative increases risk for progression to esophageal adenocarcinoma in patients with Barrett’s esophagus. Am J Gastroenterol. 2017; 309:112(1).

  • 5. Anaparthy R, Gaddam S, Kanakadandi V, et al. Association between length of Barrett’s esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. Clin Gastroenterol Hepatol. 2013;11(11):1430-6.

  • 6. Helen G. Coleman, Shivaram Bhat, Brian T. Johnston, Damian Mcmanus, Anna T. Gavin, and Liam J. Murray. Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett’s esophagus. Gastroenterology. 2012;142(2):233-40.

  • 7. Wolf WA, Pasricha S, Cotton C, et al. Incidence of esophageal adenocarcinoma and causes of mortality after radiofrequency ablation of Barrett’s esophagus. Gastroenterology. 2015;149(7):1752-1761.

  • 8. Sharma, P., Shaheen, N., Katzka, D., Bergman, J.G.H.M. AGA Clinical Practice Update on Endoscopic Treatment of Barrett's Esophagus with Dysplasia and /or Early Cancer: Expert Review. Gastroenterology. 2020. Vol 158(3): P760-769.

  • 9. Shaheen NJ, Falk GW, Iyer PG, Gerson, LB. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. The American Journal of Gastroenterology. 2016;111(1):30–50.

  • 10. https://www.cancer.org/cancer/esophagus-cancer/about/key-statistics.html Accessed date: 11/14/2022

     Visit Site